Millennium Pharmaceuticals, Inc. clinical trials

Acquired by Takeda, May 9, 2008 · source ↗

The registry lists 178 studies whose lead sponsor is Millennium Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 178. List all 178 → · All Takeda studies →

• Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)CompletedNCT03990649Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedNCT01659658Phase 3

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Phase 3

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)CompletedNCT03724916Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy ParticipantsCompletedNCT03811834Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy KidneysCompletedNCT04056455Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic FunctionCompletedNCT04056468Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of Pevonedistat in Adult East Asian ParticipantsCompletedNCT02782468Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic HypersomniaCompletedNCT04091438Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01850524Phase 3

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) TransplantationCompletedNCT03657160Phase 3

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac DiseaseCompletedNCT03701555Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid TumorsCompletedNCT03330106Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)CompletedNCT03439280Phase 1/2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedNCT03170882Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic GastroparesisCompletedNCT03544229Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion MutationsApproved for marketingNCT04535557

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid TumorsCompletedNCT03486314Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedNCT00853307Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male ParticipantsCompletedNCT04454918Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerCompletedNCT02725268Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedNCT02724020Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsCompletedNCT03261947Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult ParticipantsCompletedNCT03849690Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)TerminatedNCT03449030Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic TumorsCompletedNCT02699749Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)CompletedNCT03268941Phase 2

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid TumorsCompletedNCT03708211Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult ParticipantsCompletedNCT04121078Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)WithdrawnNCT03888534Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIBCompletedNCT01953783Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT03928327Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaCompletedNCT01425008Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult ParticipantsCompletedNCT03870555Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsCompletedNCT01862328Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female ParticipantsTerminatedNCT03501069Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)CompletedNCT04091425Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain AmyloidosisCompletedNCT01318902Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Dose Escalation Study of MLN0128 in Participants With Advanced MalignanciesCompletedNCT01058707Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or OlderCompletedNCT01814826Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic MalignanciesCompletedNCT02412722Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT02327169Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda

• A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy ParticipantsCompletedNCT03482453Phase 1

  Sponsor listed in the registry: Millennium Pharmaceuticals, Inc. · First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda